Combination PPAR𝛾 and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2

Table 4

Microarray Analysis of A375(DRO) cells after TZD/rexinoid combination treatment—2-fold down regulated with ROSI alone.

Gene Symbol	fold change	GenBank ID
ORC4L	$-15.9$	NM_002552
TAF12	$-8.9$	NM_005644
ZNF443	$-8.1$	NM_005815
HIGD1A	$-8.0$	NM_032775
CYB5R2	$-7.9$	NM_001039580
DAZAP2	$-7.5$	NM_005726
STK32B	$-7.1$	NM_024754
ZBTB43	$-6.7$	NM_014007
CAMTA1	$-6.6$	NM_015215
HCG4	$-6.4$	NR_002139
BSCL2 /// HNRNPUL2	$-6.3$	NM_001079559
SLC39A4	$-6.0$	NM_017414
DZIP3	$-6.0$	NM_014648
MSRB2	$-6.0$	NM_018009
KLHL22	$-5.8$	NM_032848
MPP5	$-5.7$	NM_024899
RNF41	$-5.6$	NM_005785
VRK3	$-5.5$	NM_030581
ABAT	$-5.4$	NM_000663
BRCA2	$-5.3$	NM_000059
RARS	$-5.3$	NM_002887